Corpus ID: 6227035

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

@article{Nagy2005DecreasedAA,
  title={Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.},
  author={P. Nagy and E. Friedl{\"a}nder and M. Tanner and A. Kapanen and K. Carraway and J. Isola and T. Jovin},
  journal={Cancer research},
  year={2005},
  volume={65 2},
  pages={
          473-82
        }
}
Overexpression of erbB2 in breast tumors is associated with poor prognosis and is a target of receptor-oriented cancer therapy. Trastuzumab (Herceptin), a monoclonal antibody against a membrane-proximal epitope in the extracellular region of erbB2, shows a therapeutic effect against a fraction of erbB2-amplified breast tumors. Unfortunately, resistance to Herceptin is common, and its cause is as yet unclear. Here we investigated the properties of erbB2 in a Herceptin-resistant cell line, JIMT-1… Expand
Resistance to Targeted Therapies in Breast Cancer
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.
  • L. Klapper, S. Glathe, +4 authors Y. Yarden
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
...
1
2
3
4
5
...